AJP - Heart Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol (April 15, 2005). doi:10.1152/ajpheart.00268.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/H660    most recent
00268.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, F.-F.
Right arrow Articles by Yan, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, F.-F.
Right arrow Articles by Yan, X.
Submitted on March 18, 2005
Accepted on March 29, 2005

Heterozygous Knock Out of the Neuregulin-1 Gene in Mice Exacerbates Doxorubicin-Induced Heart Failure

Fen-Fen Liu1, James R Stone2, Adam J Schuldt1, Katashi Okoshi1, Marina P Okoshi1, Masaharu Nakayama1, Kalon K Ho1, Warren J Manning1, Mark A Marchionni3, Beverly H Lorell1, James P Morgan1, and Xinhua Yan1*

1 Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
2 Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
3 NRG Biotech, Arlington, MA, USA

* To whom correspondence should be addressed. E-mail: xyan{at}bidmc.harvard.edu.

Neuregulins and their erbB receptors are essential for cardiac development and postulated to be cardioprotective in the presence of injury in the postnatal heart. We tested the hypothesis that the development of doxorubicin-induced cardiotoxicity in vivo is more severe in mice with heterozygous knock out of the neuregulin-1 gene (NRG-1+/-) compared with wild type mice (WT). Three-month old NRG-1+/- and WT mice were injected with a single dose of doxorubicin (20 mg/kg, i.p.). Survival was analyzed by the Kaplan-Meier approach. Left ventricular (LV) function and signaling pathways were analyzed four days after treatment. Fifteen days after treatment, survival was significantly lower in doxorubicin-treated NRG-1+/- (NRG-1+/--Dox) compared with doxorubicin-treated wild type mice (WT-Dox) (15 vs. 33%, p<0.01). LV mass was significantly lower in NRG-1+/--Dox, but not in WT-Dox compared with non-treated animals. LV systolic pressure and LV midwall fractional shortening were significantly lower in NRG-1+/--Dox compared with WT-Dox. LV protein levels of NRG-1, erbB2 and erbB4 receptors were similar in WT-Dox and NRG-1+/--Dox. However, levels of phosphorylated erbB2, Akt and ERK1/2 were significantly decreased in NRG-1+/--Dox compared with WT-Dox. A significant decrease in phosphorylated P70S6K levels was also observed in NRG-1+/--Dox compared with non-treated NRG-1+/-. These results demonstrate that heterozygous knock out of the neuregulin-1 gene worsens survival and LV function in the presence of doxorubicin-induced cardiac injury in vivo. This is associated with the depression of activation of the erbB2 receptor as well as Akt, P70S6K and ERK1/2 pathways.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Bian, M. Sun, M. Silver, K. K. L. Ho, M. A. Marchionni, A. O. Caggiano, J. R. Stone, I. Amende, T. G. Hampton, J. P. Morgan, et al.
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H1974 - H1983.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. Ky, S. E. Kimmel, R. N. Safa, M. E. Putt, N. K. Sweitzer, J. C. Fang, D. B. Sawyer, and T. P. Cappola
Neuregulin-1{beta} Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure
Circulation, July 28, 2009; 120(4): 310 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Fang, J. Gu, F. Xie, M. Behr, W. Yang, E. D. Abel, and X. Ding
Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity
Drug Metab. Dispos., August 1, 2008; 36(8): 1722 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. R.J. H. Bird and S. M. Swain
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Lemmens, K. Doggen, and G. W. De Keulenaer
Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure
Circulation, August 21, 2007; 116(8): 954 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Gabrielson, D. Bedja, S. Pin, A. Tsao, L. Gama, B. Yuan, and N. Muratore
Heat Shock Protein 90 and ErbB2 in the Cardiac Response to Doxorubicin Injury
Cancer Res., February 15, 2007; 67(4): 1436 - 1441.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. J. Freedman and G. S. Ginsburg
Novel--and "Neu"--Therapeutic Possibilities for Heart Failure
J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1448 - 1450.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.